Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.

By N. Anavekar, J. McMurray, E. Velazquez, S. Solomon, L. Køber, J. Rouleau, Harvey D. White, R. Nordlander, A. Maggioni, K. Dickstein and 4 more. New England Journal of Medicine, 2004

1,981 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Nephrology

View Paper: https://www.semanticscholar.org/paper/1ba494ceb331a9a56331a5e3021bb855307ef348

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Jeroen J. Bax
2. M. Woodward
3. Rick A. Nishimura
4. J. Halperin
5. Gerasimos Filippatos
6. M. Creager
7. C. Yancy

Citations in the corpus

• 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. (2008, background): “Current opinion and most of the limited evidence vailable suggest that when appropriately monitored, cariovascular medications and interventional strategies can be pplied safely in those with renal impairment and provide herapeutic benefit (64).”
• Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. (2007, neutral): “Such effects of treatment are important in view of the high risk of progression to end stage renal failure and premature death in patients who develop diabetic nephropathy, as well as the emerging evidence of substantial cardiovascular risks associated with progression of renal impairment.(22,23)”
• Cardiorenal syndrome. (2008, positive): “…Enlargement], and VALIANT [Valsartan in Acute Myocardial Infarction]) in which the authors excluded individuals with baseline serum creatinine of (cid:5) 2.5 mg/dl, reduced renal function was associated with significantly greater mortality and adverse cardiovascular event rates (108–111).”
• Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. (2008, background): “Patients with renal dysfunction The 2-year mortality rate among STEMI patients with end-stage renal disease (creatinine clearance ,30 mL/min) is much higher than in the general population,(170) which might be explained on the one hand by a higher proportion of cardiovascular risk factors and on the ”